You are here: Home » PTI Stories » National » News
Business Standard

'Gene editing tool may help cure sickle cell disease'

Press Trust of India  |  Los Angeles 

Scientists, using the CRISPR-Cas9 gene editing tool, have found a way to fix the mutated gene responsible for sickle cell disease, which leads to anemia, painful blood blockages and early death.

For the first time, researchers have corrected the mutation in a proportion of stem cells that is high enough to produce a substantial benefit in sickle cell patients.



They hope to re-infuse patients with the edited stem cells and alleviate symptoms of the disease, which primarily afflicts those of African descent.

"There is still a lot of work to be done before this approach might be used in the clinic, but we're hopeful that it will pave the way for new kinds of treatment for patients with sickle cell disease," said Jacob Corn, from University of California, Berkeley.

In tests in mice, the genetically engineered stem cells stuck around for at least four months after transplantation, an important benchmark to ensure that any potential therapy would be lasting.

"This is an important advance because for the first time we show a level of correction in stem cells that should be sufficient for a clinical benefit in persons with sickle cell anemia," said Mark Walters, from University of California, San Francisco.

Sickle cell disease is a recessive genetic disorder caused by a single mutation in both copies of a gene coding for beta-globin, a protein that forms part of the oxygen-carrying molecule hemoglobin.

This homozygous defect causes hemoglobin molecules to stick together, deforming red blood cells into a characteristic "sickle" shape.

These misshapen cells get stuck in blood vessels, causing blockages, anemia, pain, organ failure and significantly shortened lifespan.

Sickle cell disease is particularly prevalent in African-Americans and the sub-Saharan African population, affecting hundreds of thousands of people worldwide.

Researchers aimed to develop genome engineering-based methods for correcting the disease-causing mutation in each patient's own stem cells to ensure that new red blood cells are healthy.

The team used CRISPR-Cas9 to correct the disease-causing mutation in hematopoietic stem cells - precursor cells that mature into red blood cells - isolated from whole blood of sickle cell patients. The corrected cells produced healthy hemoglobin, which mutated cells do not make at all.

"Sickle cell disease is just one of many blood disorders caused by a single mutation in the genome," Corn said.

"It's very possible that other researchers and clinicians could use this type of gene editing to explore ways to cure a large number of diseases," he said.

The findings were published in the journal Science Translational Medicine.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

'Gene editing tool may help cure sickle cell disease'

Scientists, using the CRISPR-Cas9 gene editing tool, have found a way to fix the mutated gene responsible for sickle cell disease, which leads to anemia, painful blood blockages and early death. For the first time, researchers have corrected the mutation in a proportion of stem cells that is high enough to produce a substantial benefit in sickle cell patients. They hope to re-infuse patients with the edited stem cells and alleviate symptoms of the disease, which primarily afflicts those of African descent. "There is still a lot of work to be done before this approach might be used in the clinic, but we're hopeful that it will pave the way for new kinds of treatment for patients with sickle cell disease," said Jacob Corn, from University of California, Berkeley. In tests in mice, the genetically engineered stem cells stuck around for at least four months after transplantation, an important benchmark to ensure that any potential therapy would be lasting. "This is an important ... Scientists, using the CRISPR-Cas9 gene editing tool, have found a way to fix the mutated gene responsible for sickle cell disease, which leads to anemia, painful blood blockages and early death.

For the first time, researchers have corrected the mutation in a proportion of stem cells that is high enough to produce a substantial benefit in sickle cell patients.

They hope to re-infuse patients with the edited stem cells and alleviate symptoms of the disease, which primarily afflicts those of African descent.

"There is still a lot of work to be done before this approach might be used in the clinic, but we're hopeful that it will pave the way for new kinds of treatment for patients with sickle cell disease," said Jacob Corn, from University of California, Berkeley.

In tests in mice, the genetically engineered stem cells stuck around for at least four months after transplantation, an important benchmark to ensure that any potential therapy would be lasting.

"This is an important advance because for the first time we show a level of correction in stem cells that should be sufficient for a clinical benefit in persons with sickle cell anemia," said Mark Walters, from University of California, San Francisco.

Sickle cell disease is a recessive genetic disorder caused by a single mutation in both copies of a gene coding for beta-globin, a protein that forms part of the oxygen-carrying molecule hemoglobin.

This homozygous defect causes hemoglobin molecules to stick together, deforming red blood cells into a characteristic "sickle" shape.

These misshapen cells get stuck in blood vessels, causing blockages, anemia, pain, organ failure and significantly shortened lifespan.

Sickle cell disease is particularly prevalent in African-Americans and the sub-Saharan African population, affecting hundreds of thousands of people worldwide.

Researchers aimed to develop genome engineering-based methods for correcting the disease-causing mutation in each patient's own stem cells to ensure that new red blood cells are healthy.

The team used CRISPR-Cas9 to correct the disease-causing mutation in hematopoietic stem cells - precursor cells that mature into red blood cells - isolated from whole blood of sickle cell patients. The corrected cells produced healthy hemoglobin, which mutated cells do not make at all.

"Sickle cell disease is just one of many blood disorders caused by a single mutation in the genome," Corn said.

"It's very possible that other researchers and clinicians could use this type of gene editing to explore ways to cure a large number of diseases," he said.

The findings were published in the journal Science Translational Medicine.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

'Gene editing tool may help cure sickle cell disease'

Scientists, using the CRISPR-Cas9 gene editing tool, have found a way to fix the mutated gene responsible for sickle cell disease, which leads to anemia, painful blood blockages and early death.

For the first time, researchers have corrected the mutation in a proportion of stem cells that is high enough to produce a substantial benefit in sickle cell patients.

They hope to re-infuse patients with the edited stem cells and alleviate symptoms of the disease, which primarily afflicts those of African descent.

"There is still a lot of work to be done before this approach might be used in the clinic, but we're hopeful that it will pave the way for new kinds of treatment for patients with sickle cell disease," said Jacob Corn, from University of California, Berkeley.

In tests in mice, the genetically engineered stem cells stuck around for at least four months after transplantation, an important benchmark to ensure that any potential therapy would be lasting.

"This is an important advance because for the first time we show a level of correction in stem cells that should be sufficient for a clinical benefit in persons with sickle cell anemia," said Mark Walters, from University of California, San Francisco.

Sickle cell disease is a recessive genetic disorder caused by a single mutation in both copies of a gene coding for beta-globin, a protein that forms part of the oxygen-carrying molecule hemoglobin.

This homozygous defect causes hemoglobin molecules to stick together, deforming red blood cells into a characteristic "sickle" shape.

These misshapen cells get stuck in blood vessels, causing blockages, anemia, pain, organ failure and significantly shortened lifespan.

Sickle cell disease is particularly prevalent in African-Americans and the sub-Saharan African population, affecting hundreds of thousands of people worldwide.

Researchers aimed to develop genome engineering-based methods for correcting the disease-causing mutation in each patient's own stem cells to ensure that new red blood cells are healthy.

The team used CRISPR-Cas9 to correct the disease-causing mutation in hematopoietic stem cells - precursor cells that mature into red blood cells - isolated from whole blood of sickle cell patients. The corrected cells produced healthy hemoglobin, which mutated cells do not make at all.

"Sickle cell disease is just one of many blood disorders caused by a single mutation in the genome," Corn said.

"It's very possible that other researchers and clinicians could use this type of gene editing to explore ways to cure a large number of diseases," he said.

The findings were published in the journal Science Translational Medicine.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard